Skip to main content

Progyny, Inc. (PGNY) Stock Analysis

Recovery setup

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Healthcare Plans

Sell if holding. Analyst target reached at $24.63 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.4).

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle;... Read more

$24.63+0.9% A.UpsideScore 6.0/10#1 of 11 Healthcare Plans
QualityF-score7 / 9FCF yield10.39%
Stop $22.88Target $24.83(analyst − 13%)A.R:R 0.1:1
Analyst target$28.55+15.9%11 analysts
$24.83our TP
$24.63price
$28.55mean
$19
$31

Sell if holding. Analyst target reached at $24.63 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.4). Chart setup: Death cross but MACD improving, RSI 80. Score 6.0/10, moderate confidence.

Passes 8/10 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.33, news boost analyst cluster(7), earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

Val6.9Qual5.4Grw6.4Mom7.3Sent7.4Ins5.0Peer4.3Tech3.4Risk4.56.0OVERALL

Recent Developments — Progyny, Inc.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Positive momentum
Risks
Analyst target reached - limited upside remaining
V7 low-quality RISK_OFF penalty: -0.5 (Q=5.4)
Leverage penalty (D/E 6.2): -1.5

Key Metrics

P/E (TTM)31.9
P/E (Fwd)11.1
Mkt Cap$1.9B
EV/EBITDA15.8
Profit Mgn5.2%
ROE14.9%
Rev Growth1.4%
Beta0.91
DividendNone
Rating analysts17

Quality Signals

Piotroski F7/9

Options Flow

P/C0.13bullish
IV54%elevated
Max Pain$10-59.4% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Support Resistance
0.6
Bollinger
1.0
Gap
5.0
52w Position
7.1
GatesA.R:R 0.1 < 1.5@spotDeath cross (50MA < 200MA)Momentum 7.3>=5.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.33NEWS BOOST ANALYST CLUSTER(7)EARNINGS PROXIMITY 78d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
80 · Overbought
↑ 20D MA↑ 50D MA↑ 200D MADEATH CROSSSupport $17.37Resistance $25.10

Price Targets

$23
$25
A.Upside+0.8%
A.R:R0.1:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Target reached (1.0% upside)
! Reward/Risk 0.1:1 at current price — below 1.5:1 minimum

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-06 (78d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is PGNY stock a buy right now?

Sell if holding. Analyst target reached at $24.63 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.4). Chart setup: Death cross but MACD improving, RSI 80. Prior stop was $22.88. Score 6.0/10, moderate confidence.

What is the PGNY stock price target?

Take-profit target: $24.83 (+0.9% upside). Prior stop was $22.88. Stop-loss: $22.88.

What are the risks of investing in PGNY?

Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.4); Leverage penalty (D/E 6.2): -1.5.

Is PGNY overvalued or undervalued?

Progyny, Inc. trades at a P/E of 31.9 (forward 11.1). TrendMatrix value score: 6.9/10. Verdict: Sell.

What do analysts say about PGNY?

17 analysts cover PGNY with a consensus score of 4.2/5. Average price target: $29.

What does Progyny, Inc. do?Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits...

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Related stocks: OSCR (Oscar Health, Inc.) · ALHC (Alignment Healthcare, Inc.) · CLOV (Clover Health Investments, Corp) · MOH (Molina Healthcare Inc)